BioGeneration Ventures (BGV) is an early-stage venture capital firm based in Naarden, Netherlands. See contact routes.
BioGeneration Ventures (BGV) is an early-stage venture capital firm based in Naarden, Netherlands, founded in 2006 by Edward van Wezel as the seed-stage arm of the Forbion-BGV platform. The firm invests primarily in European biotechnology, medtech, and diagnostics companies that translate academic research into novel therapeutics addressing unmet medical needs. BGV typically acts as a lead investor or company creator, focusing on seed to early-growth stages with a geographic emphasis on Europe, particularly the Benelux region and Germany. Its typical check size ranges from €100,000 to €1 million, with a sweet spot around €500,000, though historical averages reach approximately $8.2 million. Notable portfolio companies include Acerta Pharma (acquired by AstraZeneca for up to $7 billion), Dezima Pharma (sold to Amgen for $1.55 billion), Synaffix, and argenx. BGV’s distinctive point of view centers on rigorous selection of projects with strong proof-of-concept potential, combining deep scientific expertise with commercial insight to guide companies through clinical development to successful exits.
Every field above is read from the StartupFundraising firm directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Netherlands when building a target list.
Investors like BioGeneration Ventures · Full investor directory · Investor access · Company funding database